1999 Publications

Make a selection to see details:

• Papers
• Books and book chapters
• Abstracts

All links listed below will open in a new window. Close the new window to return to this page.

Papers

• Burnett JR, Wilcox LJ, Telford DE, Kleinstiver SJ, Barrett PHR, Newton RS, Huff MW. The magnitude of decrease in hepatic VLDL apoB secretion is determined by the extent of HMG-CoA reductase inhibition in miniature pigs. Endocrinology 1999; 140: 5293-5302. [C]
• Burnett JR, Wilcox LJ, Telford DE, Kleinstiver SJ, Barrett PH, Newton RS, Huff MW. Inhibition of ACAT by avasimibe decreases both VLDL and LDL apolipoprotein B production in miniature pigs. J Lipid Res. 1999 Jul;40(7):1317-27. [C]
• Caumo, A., Vicini P, J.J. Zachwieja, A. Avogaro, K. Yarasheski, D.M. Bier and C. Cobelli. Undermodeling affects minimal model indices: insights from a two-compartment model. Am J Physiol 276: E1171-E1193, 1999 [C]
• Cobelli C, Caumo A, Omenetto M. Minimal model SG overestimation and SI underestimation: improved accuracy by a Bayesian two-compartment model. Am J Physiol 277: E481-E488, 1999. [C]
• Colvin PL, Morguchi E, Barrett PHR, Parks JS, Rudel LL. Small HDL particles containing two apoA-I molecules are precursors in vivo to medium and large HDL particles containing three and four apoA-I molecules in nonhuman primates. J. Lipid Res. 40: 1782-1792, 1999. [C]
• Fabris L, Jemmolo RM, Toffolo G, Paleari D, Viaggi S, Rigon M, Casagrande F, Lirussi F, Strazzabosco M, Cobelli C, Okolicsanyi L. The monoethylglycinexylidide test for grading of liver cirrhosis. Aliment Pharmacol Ther. 1999 Jan;13(1):67-75. [C]
• Foster, DM and PHR Barrett. Developing and testing integrated multicompartmental models to describe a single-input multiple-output study using the SAAM II software system. Sixth International Radiopharmaceutical Dosimetry Symposium. ORISE Press, Oak Ridge, TN. 577 - 599, 1999. [D]
• Konrad, T., Vicini P, K. Kusterer, A. Höflich, A. Assadkhani, H.J. Böhles, A. Sewell, H.J. Tritschler, C. Cobelli, K.H. Usadel. alpha-Lipoic acid treatment decreases serum lactate and pyruvate concentrations and improves glucose effectiveness in lean and obese patients with type 2 diabetes. Diabetes Care 22: 280287, 1999. [C]
• Konrad, T., Vicini P, S. Zeuzem, G. Toffolo, D. Briem, J. Lormann, G. Herrmann, D. Wittman, T. Lenz, K. Kusterer, G. Teuber, C. Cobelli and K.-H. Usadel. Interferon-alpha improves glucose tolerance in diabetic and non-diabetic patients with HCV-induced liver disease. Experimental and Clinical Endocrinology and Diabetes 107: 343-349, 1999. [C]
• Lamarche B, Uffelman KD, Carpentier A, Cohn JS, Steiner G, Barrett PH, Lewis GF. Triglyceride enrichment of HDL enhances in vivo metabolic clearance of HDL apo A-I in healthy men. J Clin Invest. 1999 Apr;103(8):1191-9. [C]
• Lau CE, Ma F, Foster DM, Falk JL. Pharmacokinetic-pharmacodynamic modeling of the psychomotor stimulant effect of cocaine after intravenous administration: timing performance deficits. J Pharmacol Exp Ther 288: 535-543, 1999. [C]
• Mardirossian, G, SP Baker, D Foster, GE Wynant, MG Hanna and AB Brill. Pharmacokinetic and disimetry comparison of two human antibody clones (99MTc-88BV50). Sixth International Radiopharmaceutical Dosimetry Symposium. ORISE Press, Oak Ridge, TN. 603 612, 1999. [C]
• Olin KL, Potter-Perogo S, Barrett PHR, Wight TN, Chait A. Lipoiprotein lipase enhances the binding of native and oxidized low density lipoproteins to versican and biglycan synthesized by cultured arterial smooth muscle cells. J. Biol. Chem. 1999; 274: 34629-34636. [C]
• Parhofer KG, Barrett PHR, Schwandt P. LDL apolipoprotein B metabolism: comparison of two methods to establish kinetic parameters. Atherosclerosis 1999; 144: 159-166. [C]
• Riches FM, Watts GF, Hua J, Stewart GR, Naoumova RP, Barrett PH. Reduction in visceral adipose tissue is associated with improvement in apolipoprotein B-100 metabolism in obese men. J Clin Endocrinol Metab. 1999 Aug;84(8):2854-61. [C]
• Sparacino G, Bonadonna R, Steinberg H, Baron A, Cobelli C. Estimation of organ transport function for recirculating indicator dilution curves. Ann Biomed Eng. 1998 Jan-Feb;26(1):128-37.
• Steinmueller, T., T. Konrad, S. Jonas, S. Tullius, W.O. Bechstein, A. Mueller, K.P. Platz, U. Neumann, Vicini P, G. Toffolo, C. Cobelli, K.H. Usadel and P. Neuhaus. The effect of cyclosporine vs FK 506 on glucose metabolism. Transplantation Proceedings 31: 1129-1130, 1999. [C]
• Sumner AE, Falkner B, Diffenderfer MR, Barrett PHR, Marsh JB.A study of the metabolism of apolipoprotein B100 in relation to insulin resistance in african american males. Proc Soc Expt Biol & Med. 1999; 22: 352-360. [C]
• Thomaseth K, Cobelli C. Generalized sensitivity functions in physiological system identification. Ann Biomed Eng. 1999 Sep-Oct;27(5):607-16. [T]
• Toffolo G, Cefalu WT, Cobelli C. Beta-cell function during insulin-modified intravenous glucose tolerance test successfully assessed by the C-peptide minimal model. Metabolism. 1999 Sep;48(9):1162-6. [C]
• Velez-Carrasco W, Lichtenstein AH, Barrett PH, Sun Z, Dolnikowski GG, Welty FK, Schaefer EJ. Human apolipoprotein A-I kinetics within triglyceride-rich lipoproteins and high density lipoproteins. J Lipid Res. 1999 Sep;40(9):1695-700. [C]
• Vicini P, Cobelli C. A priori identifiability of distributed models of blood-tissue exchange. Ann Biomed Eng. 1999 Mar-Apr;27(2):200-7. [T]
• Vicini P, Caumo A, Cobelli C. Glucose effectiveness and insulin sensitivity from the minimal models: consequences of undermodeling assessed by Monte Carlo simulation. IEEE Trans Biomed Eng. 1999 Feb;46(2):130-7. [T]
• Vicini, P., C.H. Pierce, R.L. Dills, M.S. Morgan and D.A. Kalman. Individual prior information in a physiological model of ²H₈-toluene kinetics: An empirical Bayes estimation strategy. Risk Analysis 19: 1127-1134, 1999. [C]
• Vicini P, Zachwieja JJ, Yarasheski KE, Bier DM, Caumo A, Cobelli C. Glucose production during an IVGTT by deconvolution: validation with the tracer-to-tracee clamp technique. Am J Physiol. 1999 Feb;276(2 Pt 1):E285-94. [C]
• Welty FK, Lichtenstein AH, Barrett PHR, Dolnikowski GG, Schaefer EJ. Human apolipoprotein B-48 and apoB-100 kinetics using stable isotopes. Arterioscler Thromb Vasc Biol 1999; 19: 2966-2974. [C]
• Wilcox LJ, Barrett PHR, Newton RS, Huff MW. Differential regulation of apolipoprotein B secretion from HepG2 cells by two HMG-CoA reductase inhibitors: Atorvastatin and Simvastatin. J. Lipid Res. 1999; 40: 1078-1089. [C]
• Wilcox LJ, Barrett PH, Newton RS, Huff MW. ApoB100 secretion from HepG2 cells is decreased by the ACAT inhibitor CI-1011: an effect associated with enhanced intracellular degradation of ApoB. Arterioscler Thromb Vasc Biol. 1999 Apr;19(4):939-49. [C]

[top of page]

Books and book chapters

• None published this year.

Abstracts

• Batal R, Tremblay M, Barrett PHR, Jacques H, Fredenrich A, Mamer O, Davignon J, Cohn JS. Plasma kinetics of apoCIII and apoE in normolipidemic and hypertriglyceridemic subjects. Circulation Suppl. 1999, I-470. [C]
• Barrett PHR, Chan R, Redgrave TG, Vasikaran S, Wang T, Martins I, Watts GF. Effect of atorvastatin on chylomicron remnant clearance in obese subjects. A study based on a novel stable-isotope breath test. Multiple risk factors in cardiovascular disease. Venice, 1999. [C]
• Barrett PHR, Twisk J, Gilian-Daniel DL, Tebon A, Wang L, Attie AD. The role of the LDL receptor in apolipoprotein B secretion. Australian Athero Soc, Melbourne, 1999. [C]
• Burnett JR, Wilcox LJ, Telford DE, Kleinstiver SJ, Barrett PHR, Newton RS, Huff MW. The Magnitude of Decrease in Hepatic VLDL ApoB secretion, in vivo, is determined by the extent of HMG-CoA reductase inhibition. Circulation Suppl. 1999, I-685. [C]
• Lichtenstein AH, Welty FK, Millar JS, Jenner JL, Dolnikowski G, Barrett PHR, Schaefer EJ. Fish consumption decreases TRl apoB48 and apoB100 production rates. Circulation Suppl. 1999, I-659. [C]
• Omenetto M, Caumo A, Cobelli C. The insulin modified IVGTT minimal model method: Improved accuracy by a Bayesian two compartment model. Diabetes 48: Supplement 1, A300: 1311, 1999. [C]
• Parhofer KG, Dinkel R, Demant T, Barrett PHR, Schwandt P. In vivo metabolism of VLDL apoprotein-B, C-III and E. Circulation Suppl. 1999, I-470. [C]
• Prigeon, R., S. Quddusi, Vicini P, B. Paty e D. D’Alessio. Glucagon-Like Peptide-1 does not alter glucose effectiveness of tissue glucose uptake in humans. Diabetes 48: Supplement 1, A290: 1267, 1999. [C]
• Redgrave TG, Martins IJ, Barrett PHR, Marais, AD, Watts GF. Metabolism of lipoprotein remnants in familial dyslipidemia assessed by a 13CO2 breath test. Australian Athero Soc, Melbourne, 1999. [C]
• Rosenfeld, M., D. Borowitz, J. Emerson, R. Gibson, L. Ingham, K. McCoy, S. McNamara, B. Montgomery, B. Ramsey, Vicini P and B. Wilmott. Safety and serum pharmacokinetics of inhaled tobramycin (TOBI) in very young CF patients. 13th North American Cystic Fibrosis Conference, October 7-10, 2000, Seattle, WA. [C]
• Spilker, M.E., Vicini P, A. Valerio, A. Avogaro and G. M. Toffolo. Epinephrine delays and antagonizes glucose and insulin effects on glucose production during an IVGTT. Diabetes 48: Supplement 1, A288: 1257, 1999. [C]
• Vicini, P., B.M. Bell and D.M. Foster. A program for population analysis of transient data. 1999 First Joint IEEE/EMBS Conference, October 13-16, 1999 Atlanta, GA. [T]
• Vicini, P., and C. Cobelli. Population minimal modeling improves precision of the standard IVGTT estimates of insulin sensitivity and glucose effectiveness. Diabetes 48: Supplement 1, A297: 1297, 1999. [C]
• Vicini, P., M. Rosenfeld, D. Borowitz, K. McCoy, S. McNamara, B. Montgomery, B. Ramsey and B. Wilmott. Population pharmacokinetics of inhaled tobramycin in cystic fibrosis patients less than 6 years of age. PharmSci Supplement 1(4), 3001, 1999. [C]

[top of page]